Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

被引：1
|
作者：
Ferrero, Simone
Grimaldi, Daniele
Arrigoni, Elena
Zaccaria, Gian Maria
Alessandria, Beatrice
Genuardi, Elisa
De Luca, Gabriele
Ghislieri, Marco
Di Rocco, Alice
Re, Alessandro
Stefoni, Vittorio
Cavallo, Federica
Boccomini, Carola
Balzarotti, Monica
Zilioli, Vittorio Ruggero
Maria, Gomes Da Silva
Arcaini, Luca
Molinari, Anna Lia
Ballerini, Filippo
Ferreri, Andres Jm
Puccini, Benedetta
Palumbo, Giuseppe A.
Galimberti, Sara
Cortelazzo, Sergio
Di Paolo, Antonello
Ladetto, Marco
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134875
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 42 条
  • [31] Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
    Dreyling, Martin
    Doorduijn, Jeanette K.
    Gine, Eva
    Jerkeman, Mats
    Walewski, Jan
    Hutchings, Martin
    Mey, Ulrich
    Riise, Jon
    Trneny, Marek
    Vergote, Vibeke K. J.
    Celli, Melania
    Shpilberg, Ofer
    da Silva, Maria Gomes
    Leppa, Sirpa
    Jiang, Linmiao
    Pott, Christiane
    Klapper, Wolfram
    Goezel, Doendue
    Schmidt, Christian
    Unterhalt, Michael
    Ladetto, Marco
    Hoster, Eva
    BLOOD, 2022, 140
  • [32] SINGLE-AGENT LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA FOLLOWING BORTEZOMIB: EFFICACY, SAFETY AND PHARMACOKINETICS FROM THE MULTICENTER PHASE II MCL-001 "EMERGE" TRIAL
    Goy, A.
    Sinha, R.
    Vose, J.
    Adler, H.
    Bernstein, S.
    Robertson, M.
    Chen, N.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Witzig, T.
    HAEMATOLOGICA, 2013, 98 : 478 - 478
  • [33] Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
    Chu, Michael P.
    Brody, Joshua
    Kohrt, Holbrook E.
    Frank, Matthew J.
    Khodadoust, Michael
    Reddy, Sunil
    Advani, Ranjana H.
    Gupta, Neel K.
    Laport, Ginna
    Maeda, Lauren S.
    Meyer, Everett
    Miklos, David B.
    Negrin, Robert
    Rezvani, Andrew R.
    Weng, Wen-Kai
    Sheehan, Kevin
    Faham, Malek
    Czerwinski, Debra K.
    Okada, Ami
    Levy, Ronald
    BLOOD, 2015, 126 (23)
  • [34] Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial
    Eve, H. E.
    Bullard, S. H.
    Rule, S. A. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 42 - 43
  • [35] The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi
    Chiappella, Annalisa
    Balzarotti, Monica
    Monagheddu, Chiara
    Cavallo, Federica
    Cabras, Maria Giuseppina
    Zanni, Manuela
    Califano, Catello
    Re, Francesca
    Congiu, Angela Giovanna
    Corradini, Paolo
    Olivieri, Attilio
    Liberati, Anna Marina
    Volpetti, Stefano
    Michieli, Mariagrazia
    Tucci, Alessandra
    Tani, Monica
    Nassi, Luca
    Mazza, Rita
    Novo, Mattia
    Pileri, Stefano A.
    Ciccone, Giovannino
    Vitolo, Umberto
    BLOOD, 2019, 134
  • [36] Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Lligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years
    Ferreri, Andres J. M.
    Sassone, Marianna
    Zaja, Francesco
    Re, Alessandro
    Spina, Michele
    Di Rocco, Alice
    Fabbri, Alberto
    Angelillo, Piera
    Stelitano, Caterina
    Frezzato, Maurizio
    Rusconi, Chiara
    Zambello, Renato
    Arcari, Annalisa
    Bertoldero, Giovanni
    De Lorenzo, Daniela
    Scarano, Eloise
    Volpetti, Stefano
    Perrone, Salvatore
    Calimeri, Teresa
    Cecchetti, Caterina
    Ciceri, Fabio
    Ponzoni, Maurilio
    BLOOD, 2018, 132
  • [37] Autologous bone marrow transplantation versus conventional chemotherapy in patients with relapsed diffuse nonHodgkin's lymphoma. Results from a prospective, randomized phase III clinical trial in 216 patients (the Parma study).
    Hagenbeek, A
    Guglielmi, C
    Chauvin, F
    vanderLely, J
    Bron, D
    Sonneveld, P
    Gisselbrecht, C
    Cahn, JY
    Harousseau, JL
    Coiffier, B
    Biron, P
    Somers, R
    Philip, T
    BLOOD, 1995, 86 (10) : 1817 - 1817
  • [38] Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
    Fenske, Timothy S.
    Wang, Xin Victoria
    Till, Brian G.
    Blum, Kristie A.
    Lunning, Matthew
    Lazarus, Hillard M.
    Fishkin, Paul A. S.
    Shields, Lale Kostakoglu
    Scott, David W.
    Lacasce, Ann S.
    Johnston, Patrick B.
    Cashen, Amanda F.
    Popplewell, Leslie L.
    Dean, Robert M.
    Ahmed, Nausheen
    Shah, Nirav N.
    Wagner-Johnston, Nina D.
    Hu, Boyu
    Dholaria, Bhagirathbhai R.
    Little, Richard F.
    Friedberg, Jonathan W.
    Leonard, John P.
    Kahl, Brad S.
    BLOOD, 2024, 144 : LBA6 - LBA8
  • [39] Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)
    Bonifazi, Francesca
    Solano, Carlos
    Wolschke, Christine
    Patriarca, Francesca
    Pini, Massimo
    Nagler, Arnon
    Selleri, Mino
    Messina, Giuseppe
    Bethge, Wolfgang A.
    Herrera Fuente, Pilar
    Duarte, Rafael F.
    Cascavilla, Nicola
    Cimminiello, Michele
    Guidi, Stefano
    Finke, Juergen
    Gallamini, Andrea
    Ferra, Christelle
    Sierra, Jorge
    Russo, Domenico
    Petrini, Mario
    Milone, Giuseppe
    Benedetti, Fabio
    Heinzelmann, Marion
    Liso, Vincenzo
    Jurado, Manuel
    Pogliani, Enrico Maria
    Narni, Franco
    Voelp, Andreas
    Bandini, Giuseppe
    Ayuk, Francis
    Kroeger, Nicolaus
    BLOOD, 2014, 124 (21)
  • [40] Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
    Vose, Julie M.
    Carter, Shelly
    Burns, Linda J.
    Ayala, Ernesto
    Press, Oliver W.
    Moskowitz, Craig H.
    Stadtmauer, Edward A.
    Mineshi, Shin
    Ambinder, Richard
    Fenske, Timothy
    Horowitz, Mary
    Fisher, Richard
    Tomblyn, Marcie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (13) : 1662 - +
12345